About Spark Therapeutics
Spark Therapeutics is a company based in Philadelphia (United States) founded in 2013 was acquired by Roche in February 2019. Spark Therapeutics has raised $82.8 million across 2 funding rounds from investors including Roche, Children's Hospital of Philadelphia and T. Rowe Price. The company has 822 employees as of December 31, 2021. Spark Therapeutics has completed 1 acquisition, including Genable Technologies. Spark Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Alnylam, ATAI and Insitro, among others.
- Headquarter Philadelphia, United States
- Employees 822 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Spark Therapeutics, Inc.
-
Annual Revenue
$64.73 M (USD)436as on Dec 31, 2018
-
Net Profit
-$78.82 M (USD)69as on Dec 31, 2018
-
EBITDA
-$193.64 M (USD)25as on Dec 31, 2018
-
Total Equity Funding
$82.8 M (USD)
in 2 rounds
-
Latest Funding Round
$72.8 M (USD), Series B
May 23, 2014
-
Investors
Roche
& 7 more
-
Employee Count
822
as on Dec 31, 2021
- Investments & Acquisitions
-
Acquired by
Roche
(Feb 22, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Spark Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
146 people
Software Development Team
120 people
Product Management Team
79 people
Senior Team
63 people
Sales and Marketing
48 people
Data Analysis and Operations Team
44 people
Principal Team
27 people
Legal and Compliance
26 people
Unlock access to complete
Funding Insights of Spark Therapeutics
Spark Therapeutics has successfully raised a total of $82.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $72.8 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spark Therapeutics
Spark Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Children's Hospital of Philadelphia and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked |
Investor details for Spark Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spark Therapeutics
Spark Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genable Technologies.
Investment portfolio details for Spark Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapy for Retinitis pigmentosa is developed using AAV vectors.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Spark Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Spark Therapeutics
Detailed financials for Spark Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spark Therapeutics Comparisons
Peer comparison for Spark Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spark Therapeutics
Spark Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Spark Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spark Therapeutics
Complete news archive for Spark Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spark Therapeutics
Spark Therapeutics was founded in 2013.
Spark Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Spark Therapeutics is a funded company, having raised a total of $82.8M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Spark Therapeutics is 822.
Annual revenue of Spark Therapeutics is $64.73M as on Dec 31, 2018.
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, United States. Focus is placed on the biotechnology sector, where gene therapies for rare diseases are developed. Engineered adeno-associated viruses are used to deliver target gene sequences for treating RPE-65 mediated inherited retinal dystrophies, choroideremia, hemophilia A and B, and neurodegenerative conditions such as Battens disease. Operations center on advancing these therapies through research and clinical development.
Spark Therapeutics has made 1 acquisition, including Genable Technologies.
Spark Therapeutics has 8 investors. Key investors include Roche, Children's Hospital of Philadelphia, T. Rowe Price, Sofinnova, and Brookside Capital.